CA2593733A1 - Procede de traitement de cephalees du type par tension nerveuse - Google Patents

Procede de traitement de cephalees du type par tension nerveuse Download PDF

Info

Publication number: CA2593733A1
Authority: CA; Canada
Prior art keywords: substance; pain; headache; substantially blocking; patients
Prior art date: 1996-11-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002593733A

Other languages

English (en)

Inventor

Jes Olesen

Lars Bendtsen

Rigmor Jensen

Ulf Madsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neuraxon Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-05

Filing date

1997-11-04

Publication date

1998-05-14

1997-11-04 Application filed by Individual filed Critical Individual

1997-11-04 Priority claimed from CA2270531A external-priority patent/CA2270531C/fr

1998-05-14 Publication of CA2593733A1 publication Critical patent/CA2593733A1/fr

Status Abandoned legal-status Critical Current

Links

208000008548 Tension-Type Headache Diseases 0.000 title claims abstract description 265
238000000034 method Methods 0.000 title claims description 157
208000002193 Pain Diseases 0.000 claims abstract description 299
230000036407 pain Effects 0.000 claims abstract description 285
239000000126 substance Substances 0.000 claims abstract description 245
238000011282 treatment Methods 0.000 claims abstract description 97
230000000694 effects Effects 0.000 claims abstract description 83
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 74
230000005540 biological transmission Effects 0.000 claims abstract description 43
102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract description 40
108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract description 40
210000000929 nociceptor Anatomy 0.000 claims abstract description 40
230000001537 neural effect Effects 0.000 claims abstract description 34
230000003247 decreasing effect Effects 0.000 claims abstract description 32
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 28
229930195712 glutamate Natural products 0.000 claims abstract description 27
239000003112 inhibitor Substances 0.000 claims abstract description 20
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 claims abstract description 19
NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 claims abstract description 17
239000003825 glutamate receptor antagonist Substances 0.000 claims abstract description 14
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 claims abstract description 10
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims abstract description 10
UYZFAUAYFLEHRC-LURJTMIESA-N L-NIO Chemical compound CC(N)=NCCC[C@H](N)C(O)=O UYZFAUAYFLEHRC-LURJTMIESA-N 0.000 claims abstract description 9
MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims abstract description 9
229960004688 venlafaxine Drugs 0.000 claims abstract description 7
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims abstract description 6
UYZFAUAYFLEHRC-UHFFFAOYSA-N NG-iminoethyl-L-ornithine Natural products CC(N)=NCCCC(N)C(O)=O UYZFAUAYFLEHRC-UHFFFAOYSA-N 0.000 claims abstract description 6
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims abstract description 5
229960003914 desipramine Drugs 0.000 claims abstract description 4
229960004801 imipramine Drugs 0.000 claims abstract description 4
230000000903 blocking effect Effects 0.000 claims description 119
210000003205 muscle Anatomy 0.000 claims description 104
230000001684 chronic effect Effects 0.000 claims description 96
230000001965 increasing effect Effects 0.000 claims description 92
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 87
230000009471 action Effects 0.000 claims description 86
208000000114 Pain Threshold Diseases 0.000 claims description 77
230000037040 pain threshold Effects 0.000 claims description 75
238000004519 manufacturing process Methods 0.000 claims description 66
102000005962 receptors Human genes 0.000 claims description 65
108020003175 receptors Proteins 0.000 claims description 65
230000002093 peripheral effect Effects 0.000 claims description 59
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 57
238000005316 response function Methods 0.000 claims description 57
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 50
238000012360 testing method Methods 0.000 claims description 49
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 47
239000000651 prodrug Substances 0.000 claims description 43
229940002612 prodrug Drugs 0.000 claims description 43
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 42
229960005305 adenosine Drugs 0.000 claims description 42
230000003993 interaction Effects 0.000 claims description 42
210000003169 central nervous system Anatomy 0.000 claims description 37
230000002708 enhancing effect Effects 0.000 claims description 36
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
230000020341 sensory perception of pain Effects 0.000 claims description 35
208000035475 disorder Diseases 0.000 claims description 33
229960003692 gamma aminobutyric acid Drugs 0.000 claims description 31
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 30
230000004044 response Effects 0.000 claims description 29
-1 3-benzylamino-phenylpiperidine Chemical compound 0.000 claims description 26
230000037324 pain perception Effects 0.000 claims description 26
210000001428 peripheral nervous system Anatomy 0.000 claims description 25
101800004538 Bradykinin Proteins 0.000 claims description 24
102400000967 Bradykinin Human genes 0.000 claims description 24
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 24
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 24
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 23
229960002870 gabapentin Drugs 0.000 claims description 23
229960002748 norepinephrine Drugs 0.000 claims description 23
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 23
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims description 20
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 20
230000004118 muscle contraction Effects 0.000 claims description 20
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 19
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 19
102400000097 Neurokinin A Human genes 0.000 claims description 19
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 claims description 19
101800000399 Neurokinin A Proteins 0.000 claims description 19
101800003906 Substance P Proteins 0.000 claims description 19
239000005557 antagonist Substances 0.000 claims description 19
230000006870 function Effects 0.000 claims description 19
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 18
230000002860 competitive effect Effects 0.000 claims description 18
230000036963 noncompetitive effect Effects 0.000 claims description 18
229940044551 receptor antagonist Drugs 0.000 claims description 18
239000002464 receptor antagonist Substances 0.000 claims description 18
208000000094 Chronic Pain Diseases 0.000 claims description 15
239000004471 Glycine Substances 0.000 claims description 15
230000009467 reduction Effects 0.000 claims description 15
108010025020 Nerve Growth Factor Proteins 0.000 claims description 14
102000007072 Nerve Growth Factors Human genes 0.000 claims description 14
GTEURKRBYDHVCE-UHFFFAOYSA-N n-benzyl-2-phenylpiperidin-3-amine Chemical compound C=1C=CC=CC=1CNC1CCCNC1C1=CC=CC=C1 GTEURKRBYDHVCE-UHFFFAOYSA-N 0.000 claims description 14
230000003213 activating effect Effects 0.000 claims description 13
108010078321 Guanylate Cyclase Proteins 0.000 claims description 12
102000014469 Guanylate cyclase Human genes 0.000 claims description 12
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 claims description 12
102000046798 Neurokinin B Human genes 0.000 claims description 12
101800002813 Neurokinin-B Proteins 0.000 claims description 12
FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 12
102000004310 Ion Channels Human genes 0.000 claims description 11
108090000862 Ion Channels Proteins 0.000 claims description 11
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 11
238000010606 normalization Methods 0.000 claims description 11
108091006146 Channels Proteins 0.000 claims description 10
235000001014 amino acid Nutrition 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 9
229960001985 dextromethorphan Drugs 0.000 claims description 9
QTDZOWFRBNTPQR-UHFFFAOYSA-N guvacine Chemical compound OC(=O)C1=CCCNC1 QTDZOWFRBNTPQR-UHFFFAOYSA-N 0.000 claims description 9
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 9
229940044601 receptor agonist Drugs 0.000 claims description 9
239000000018 receptor agonist Substances 0.000 claims description 9
230000008447 perception Effects 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 7
GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims description 7
QSSNLQPWTLQYTB-UHFFFAOYSA-N 4-(1-hydroxy-4,4,5,5-tetramethyl-3-oxidoimidazol-3-ium-2-yl)benzoic acid Chemical compound CC1(C)C(C)(C)N(O)C(C=2C=CC(=CC=2)C(O)=O)=[N+]1[O-] QSSNLQPWTLQYTB-UHFFFAOYSA-N 0.000 claims description 7
PQCAUHUKTBHUSA-UHFFFAOYSA-N 7-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1NN=C2 PQCAUHUKTBHUSA-UHFFFAOYSA-N 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 7
YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims description 7
108010040722 Neurokinin-2 Receptors Proteins 0.000 claims description 7
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
102100037342 Substance-K receptor Human genes 0.000 claims description 7
150000001413 amino acids Chemical class 0.000 claims description 7
BKGWACHYAMTLAF-BYPYZUCNSA-N l-thiocitrulline Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)S BKGWACHYAMTLAF-BYPYZUCNSA-N 0.000 claims description 7
229960004572 pizotifen Drugs 0.000 claims description 7
239000011591 potassium Substances 0.000 claims description 7
229910052700 potassium Inorganic materials 0.000 claims description 7
229910001415 sodium ion Inorganic materials 0.000 claims description 7
RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 claims description 7
DDOQBQRIEWHWBT-VKHMYHEASA-N (2S)-2-amino-4-phosphonobutanoic acid Chemical compound OC(=O)[C@@H](N)CCP(O)(O)=O DDOQBQRIEWHWBT-VKHMYHEASA-N 0.000 claims description 6
BFNKQTIJVFGCKQ-PDJGWCFMSA-N (2S,4R)-4-hydroxy-1-[(1-methyl-3-indolyl)-oxomethyl]-N-[(2S)-1-[methyl-(phenylmethyl)amino]-3-(2-naphthalenyl)-1-oxopropan-2-yl]-2-pyrrolidinecarboxamide Chemical compound O=C([C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C=1C2=CC=CC=C2N(C)C=1)N(C)CC1=CC=CC=C1 BFNKQTIJVFGCKQ-PDJGWCFMSA-N 0.000 claims description 6
IORPOFJLSIHJOG-UHFFFAOYSA-N 3,7-dimethyl-1-prop-2-ynylpurine-2,6-dione Chemical compound CN1C(=O)N(CC#C)C(=O)C2=C1N=CN2C IORPOFJLSIHJOG-UHFFFAOYSA-N 0.000 claims description 6
BANYJBHWTOJQDU-GDLZYMKVSA-N 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]-1-piperidinyl]ethyl]-1H-indole Chemical compound C1([S@](=O)CC2(OC)CCN(CCC=3C4=CC(F)=CC=C4NC=3)CC2)=CC=CC=C1 BANYJBHWTOJQDU-GDLZYMKVSA-N 0.000 claims description 6
OFUDZKKOKPGXOH-UHFFFAOYSA-N 8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide Chemical compound C12=CC=3OCOC=3C=C2C(C)N(C(=O)NCCC)N=C1C1=CC=C(N)C=C1 OFUDZKKOKPGXOH-UHFFFAOYSA-N 0.000 claims description 6
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 6
ZPJJGAUEQIVPRW-UHFFFAOYSA-N chembl330795 Chemical compound C1=2CN(C)CC=2C(S(=O)(=O)N(C)C)=CC2=C1NC(O)=C2N=O ZPJJGAUEQIVPRW-UHFFFAOYSA-N 0.000 claims description 6
YYJGBEZPVOUBMJ-KRFCICRISA-N cyclohexyl-[(cyclohexylamino)-[[(2s)-3-naphthalen-2-yl-1-oxo-1-[4-(tributylphosphaniumylmethyl)anilino]propan-2-yl]amino]methylidene]azanium;dichloride Chemical compound Cl.[Cl-].C1=CC(C[P+](CCCC)(CCCC)CCCC)=CC=C1NC(=O)[C@@H](NC(NC1CCCCC1)=NC1CCCCC1)CC1=CC=C(C=CC=C2)C2=C1 YYJGBEZPVOUBMJ-KRFCICRISA-N 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
STIRHCNEGQQBOY-QEYWKRMJSA-N ly-235,959 Chemical compound C1[C@@H](CP(O)(O)=O)CC[C@H]2CN[C@H](C(=O)O)C[C@H]21 STIRHCNEGQQBOY-QEYWKRMJSA-N 0.000 claims description 6
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 6
BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims description 5
CUVGUPIVTLGRGI-SSDOTTSWSA-N (2r)-4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-SSDOTTSWSA-N 0.000 claims description 5
DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 claims description 5
UCKHICKHGAOGAP-KGLIPLIRSA-N (2s,4r)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid Chemical compound N([C@@H]1C[C@H](NC2=CC(Cl)=CC(Cl)=C21)C(=O)O)C(=O)NC1=CC=CC=C1 UCKHICKHGAOGAP-KGLIPLIRSA-N 0.000 claims description 5
HCKUBNLZMKAEIN-GSVOUGTGSA-N (3r)-3-amino-1-hydroxypyrrolidin-2-one Chemical compound N[C@@H]1CCN(O)C1=O HCKUBNLZMKAEIN-GSVOUGTGSA-N 0.000 claims description 5
ZXFRFPSZAKNPQQ-ZRUFSTJUSA-N (3r,4as,6s,8as)-6-[2-(2h-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid Chemical compound C([C@H]1C[C@H]2C[C@@H](NC[C@H]2CC1)C(=O)O)CC=1N=NNN=1 ZXFRFPSZAKNPQQ-ZRUFSTJUSA-N 0.000 claims description 5
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 claims description 5
LSTPKMWNRWCNLS-UHFFFAOYSA-N 1-amino-2,3-dihydroindene-1,5-dicarboxylic acid Chemical compound OC(=O)C1=CC=C2C(N)(C(O)=O)CCC2=C1 LSTPKMWNRWCNLS-UHFFFAOYSA-N 0.000 claims description 5
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 5
UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 claims description 5
BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims description 5
YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims description 5
239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 claims description 5
SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 claims description 5
MJMJVOWTLOXTME-UHFFFAOYSA-N 5,7-dinitroquinoxaline-2,3-dione Chemical compound O=C1C(=O)N=C2C=C([N+](=O)[O-])C=C([N+]([O-])=O)C2=N1 MJMJVOWTLOXTME-UHFFFAOYSA-N 0.000 claims description 5
AVBSIKMUAFYZAV-UHFFFAOYSA-N 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2 AVBSIKMUAFYZAV-UHFFFAOYSA-N 0.000 claims description 5
GDSGJOIKTYTOQG-UHFFFAOYSA-N 9-methyl-6-nitro-3-oxo-7,8,9,10-tetrahydro-4h-pyrido[4,3-h]quinoxalin-9-ium-2-olate Chemical compound N1C(=O)C(=O)NC2=C(CN(C)CC3)C3=C([N+]([O-])=O)C=C21 GDSGJOIKTYTOQG-UHFFFAOYSA-N 0.000 claims description 5
239000000775 AMPA receptor antagonist Substances 0.000 claims description 5
229940098747 AMPA receptor antagonist Drugs 0.000 claims description 5
QVZCXCJXTMIDME-UHFFFAOYSA-N Biopropazepan Trimethoxybenzoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN2CCN(CCCOC(=O)C=3C=C(OC)C(OC)=C(OC)C=3)CCC2)=C1 QVZCXCJXTMIDME-UHFFFAOYSA-N 0.000 claims description 5
LFBZZHVSGAHQPP-UHFFFAOYSA-N GYKI 52466 Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 LFBZZHVSGAHQPP-UHFFFAOYSA-N 0.000 claims description 5
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 5
KRVDMABBKYMBHG-UHFFFAOYSA-N Isoguvacine Chemical compound OC(=O)C1=CCNCC1 KRVDMABBKYMBHG-UHFFFAOYSA-N 0.000 claims description 5
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 5
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 5
LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 claims description 5
IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims description 5
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims description 5
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 5
WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 5
SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 5
FVYRUSCZCWSFLT-UHFFFAOYSA-N fostedil Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1C1=NC2=CC=CC=C2S1 FVYRUSCZCWSFLT-UHFFFAOYSA-N 0.000 claims description 5
UMLFDVOHVJPDIZ-UHFFFAOYSA-N hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride Chemical compound Cl.[O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CN=C1 UMLFDVOHVJPDIZ-UHFFFAOYSA-N 0.000 claims description 5
QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 claims description 5
239000002873 kainic acid receptor antagonist Substances 0.000 claims description 5
229960003299 ketamine Drugs 0.000 claims description 5
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 5
OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 claims description 5
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 5
YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 claims description 5
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 5
229960001785 mirtazapine Drugs 0.000 claims description 5
CVXJAPZTZWLRBP-MUUNZHRXSA-N n-[(2r)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1h-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide Chemical compound COC1=CC=CC=C1CN(C(C)=O)C[C@H](NC(=O)CN1CCC(CC1)N1CCCCC1)CC1=CNC2=CC=CC=C12 CVXJAPZTZWLRBP-MUUNZHRXSA-N 0.000 claims description 5
PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 claims description 5
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 5
HDDNYFLPWFSBLN-ZSHCYNCHSA-N tropanyl 3,5-dimethylbenzoate Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(C)=CC(C)=C1 HDDNYFLPWFSBLN-ZSHCYNCHSA-N 0.000 claims description 5
AIIXYCDTEGICEE-HZVAOYAWSA-N win-51708 Chemical compound C1=CC=C2N(C=C3C(C[C@@H]4CC[C@@H]5[C@@H]([C@]4(C3)C)CC[C@]3([C@H]5CC[C@@]3(O)C#C)C)=N3)C3=NC2=C1 AIIXYCDTEGICEE-HZVAOYAWSA-N 0.000 claims description 5
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 claims description 5
239000002999 4 aminobutyrate aminotransferase inhibitor Substances 0.000 claims description 4
102000000506 Adenosine A2 Receptors Human genes 0.000 claims description 4
108010041368 Adenosine A2 Receptors Proteins 0.000 claims description 4
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
229960002896 clonidine Drugs 0.000 claims description 4
229950005455 eliprodil Drugs 0.000 claims description 4
229960003667 flupirtine Drugs 0.000 claims description 4
HTDFEXRUDGWNHA-UHFFFAOYSA-N lifarizine Chemical compound CC=1NC(C=2C=CC(C)=CC=2)=NC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 HTDFEXRUDGWNHA-UHFFFAOYSA-N 0.000 claims description 4
229960002296 paroxetine Drugs 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
229960005155 tirilazad Drugs 0.000 claims description 4
FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims description 3
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims description 3
229940091860 GABA uptake inhibitor Drugs 0.000 claims description 3
229940127337 Glycine Antagonists Drugs 0.000 claims description 3
101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 3
102100037346 Substance-P receptor Human genes 0.000 claims description 3
102100034195 Thrombopoietin Human genes 0.000 claims description 3
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
229960002610 apraclonidine Drugs 0.000 claims description 3
229960000623 carbamazepine Drugs 0.000 claims description 3
229960004253 dexmedetomidine Drugs 0.000 claims description 3
229960001079 dilazep Drugs 0.000 claims description 3
229960002768 dipyridamole Drugs 0.000 claims description 3
239000003623 enhancer Substances 0.000 claims description 3
229960003472 felbamate Drugs 0.000 claims description 3
229960000326 flunarizine Drugs 0.000 claims description 3
229950006562 fostedil Drugs 0.000 claims description 3
239000002843 gaba uptake inhibitor Substances 0.000 claims description 3
239000003126 guanylate cyclase inhibitor Substances 0.000 claims description 3
108700023918 icatibant Proteins 0.000 claims description 3
229960001062 icatibant Drugs 0.000 claims description 3
SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims description 3
229960001848 lamotrigine Drugs 0.000 claims description 3
CHFSOFHQIZKQCR-UHFFFAOYSA-N licostinel Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2[N+](=O)[O-] CHFSOFHQIZKQCR-UHFFFAOYSA-N 0.000 claims description 3
229960004194 lidocaine Drugs 0.000 claims description 3
229950009851 lubeluzole Drugs 0.000 claims description 3
229960004640 memantine Drugs 0.000 claims description 3
229950006180 metapramine Drugs 0.000 claims description 3
229960003793 midazolam Drugs 0.000 claims description 3
SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 claims description 3
229950000659 remacemide Drugs 0.000 claims description 3
229960004181 riluzole Drugs 0.000 claims description 3
229960001918 tiagabine Drugs 0.000 claims description 3
229960002872 tocainide Drugs 0.000 claims description 3
229950008832 tropanserin Drugs 0.000 claims description 3
229960005318 vigabatrin Drugs 0.000 claims description 3
229960001600 xylazine Drugs 0.000 claims description 3
229940122155 Bradykinin receptor antagonist Drugs 0.000 claims description 2
102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 2
108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 2
102000003923 Protein Kinase C Human genes 0.000 claims description 2
108090000315 Protein Kinase C Proteins 0.000 claims description 2
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims description 2
229960003998 ifenprodil Drugs 0.000 claims description 2
229950003413 lifarizine Drugs 0.000 claims description 2
239000003514 metabotropic receptor agonist Substances 0.000 claims description 2
229960002036 phenytoin Drugs 0.000 claims description 2
102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 9
102400000096 Substance P Human genes 0.000 claims 8
239000000816 peptidomimetic Substances 0.000 claims 5
229940103988 Adenosine uptake inhibitor Drugs 0.000 claims 4
241001367053 Autographa gamma Species 0.000 claims 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 claims 3
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
239000003512 metabotropic receptor antagonist Substances 0.000 claims 3
SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 claims 3
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
GQSARBOWRIBUBV-UHFFFAOYSA-N 1-hydroxy-4,5-dihydroimidazole Chemical compound ON1CCN=C1 GQSARBOWRIBUBV-UHFFFAOYSA-N 0.000 claims 2
SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 claims 2
MADORZDTLHDDEN-UHFFFAOYSA-N 1-piperidin-1-ylethanol Chemical compound CC(O)N1CCCCC1 MADORZDTLHDDEN-UHFFFAOYSA-N 0.000 claims 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
MSYFITFSZJKRQJ-UHFFFAOYSA-N 4,5-dihydroimidazol-1-amine Chemical compound NN1CCN=C1 MSYFITFSZJKRQJ-UHFFFAOYSA-N 0.000 claims 2
RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 claims 2
101150007969 ADORA1 gene Proteins 0.000 claims 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
150000001483 arginine derivatives Chemical class 0.000 claims 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
235000010290 biphenyl Nutrition 0.000 claims 2
239000004305 biphenyl Substances 0.000 claims 2
BWEFEUTYNRSOKX-IZZDOVSWSA-N chembl3212774 Chemical compound C1=CC=C2C(/C=N/O)=CNC2=C1 BWEFEUTYNRSOKX-IZZDOVSWSA-N 0.000 claims 2
NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 claims 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical class C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims 2
LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 claims 2
150000003053 piperidines Chemical class 0.000 claims 2
XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical class OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 claims 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical class OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 claims 1
LSROBYZLBGODRN-UHFFFAOYSA-N 1-aminopyrrolidin-2-one Chemical compound NN1CCCC1=O LSROBYZLBGODRN-UHFFFAOYSA-N 0.000 claims 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
WSWPCNMLEVZGSM-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1CCN WSWPCNMLEVZGSM-UHFFFAOYSA-N 0.000 claims 1
RQKDTQACQPHOQL-UHFFFAOYSA-N 3h-2,3-benzodiazepine Chemical compound C1=NNC=CC2=CC=CC=C21 RQKDTQACQPHOQL-UHFFFAOYSA-N 0.000 claims 1
LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 claims 1
QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 claims 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
108010060263 Adenosine A1 Receptor Proteins 0.000 claims 1
102000030814 Adenosine A1 receptor Human genes 0.000 claims 1
108060003345 Adrenergic Receptor Proteins 0.000 claims 1
102000017910 Adrenergic receptor Human genes 0.000 claims 1
229940094419 Guanylate cyclase inhibitor Drugs 0.000 claims 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
229940123134 Nitric oxide inhibitor Drugs 0.000 claims 1
150000003835 adenosine derivatives Chemical class 0.000 claims 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
229960003805 amantadine Drugs 0.000 claims 1
229960000836 amitriptyline Drugs 0.000 claims 1
229940049706 benzodiazepine Drugs 0.000 claims 1
UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 claims 1
239000003152 bradykinin antagonist Substances 0.000 claims 1
239000003823 glutamate receptor agonist Substances 0.000 claims 1
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
150000002332 glycine derivatives Chemical class 0.000 claims 1
239000002430 glycine receptor antagonist Substances 0.000 claims 1
150000004050 homopiperazines Chemical class 0.000 claims 1
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
229940091173 hydantoin Drugs 0.000 claims 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 1
150000003230 pyrimidines Chemical class 0.000 claims 1
206010019233 Headaches Diseases 0.000 abstract description 284
231100000869 headache Toxicity 0.000 abstract description 259
206010064012 Central pain syndrome Diseases 0.000 abstract description 58
206010070834 Sensitisation Diseases 0.000 abstract description 52
230000008313 sensitization Effects 0.000 abstract description 52
230000007423 decrease Effects 0.000 abstract description 16
230000005062 synaptic transmission Effects 0.000 abstract description 15
229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract description 3
210000002569 neuron Anatomy 0.000 description 52
208000021642 Muscular disease Diseases 0.000 description 50
230000002123 temporal effect Effects 0.000 description 49
230000007246 mechanism Effects 0.000 description 48
238000001514 detection method Methods 0.000 description 45
230000037325 pain tolerance Effects 0.000 description 42
238000002567 electromyography Methods 0.000 description 41
230000001667 episodic effect Effects 0.000 description 40
239000003814 drug Substances 0.000 description 36
238000002559 palpation Methods 0.000 description 36
229940079593 drug Drugs 0.000 description 34
230000003040 nociceptive effect Effects 0.000 description 30
230000001404 mediated effect Effects 0.000 description 29
208000004454 Hyperalgesia Diseases 0.000 description 27
210000001519 tissue Anatomy 0.000 description 26
239000000835 fiber Substances 0.000 description 24
206010027599 migraine Diseases 0.000 description 23
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 21
208000019695 Migraine disease Diseases 0.000 description 21
230000003502 anti-nociceptive effect Effects 0.000 description 21
208000000112 Myalgia Diseases 0.000 description 19
229940035676 analgesics Drugs 0.000 description 19
239000000730 antalgic agent Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 19
230000001936 parietal effect Effects 0.000 description 19
230000008602 contraction Effects 0.000 description 18
238000011161 development Methods 0.000 description 18
230000018109 developmental process Effects 0.000 description 18
229940049906 glutamate Drugs 0.000 description 18
210000000278 spinal cord Anatomy 0.000 description 18
230000008544 heat pain detection Effects 0.000 description 17
108091008700 nociceptors Proteins 0.000 description 17
230000002401 inhibitory effect Effects 0.000 description 16
230000002035 prolonged effect Effects 0.000 description 16
210000000966 temporal muscle Anatomy 0.000 description 16
210000001170 unmyelinated nerve fiber Anatomy 0.000 description 16
230000001473 noxious effect Effects 0.000 description 15
239000000902 placebo Substances 0.000 description 15
229940068196 placebo Drugs 0.000 description 15
210000004044 posterior horn cell Anatomy 0.000 description 15
230000000638 stimulation Effects 0.000 description 15
241000700159 Rattus Species 0.000 description 14
230000004913 activation Effects 0.000 description 14
230000002964 excitative effect Effects 0.000 description 14
208000035154 Hyperesthesia Diseases 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000003387 muscular Effects 0.000 description 13
230000002459 sustained effect Effects 0.000 description 13
102100024304 Protachykinin-1 Human genes 0.000 description 12
206010053552 allodynia Diseases 0.000 description 12
230000000069 prophylactic effect Effects 0.000 description 12
238000003786 synthesis reaction Methods 0.000 description 12
230000002747 voluntary effect Effects 0.000 description 12
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 11
230000008859 change Effects 0.000 description 11
206010001497 Agitation Diseases 0.000 description 10
206010020751 Hypersensitivity Diseases 0.000 description 10
239000000556 agonist Substances 0.000 description 10
238000011156 evaluation Methods 0.000 description 10
208000013465 muscle pain Diseases 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
230000001953 sensory effect Effects 0.000 description 10
230000002269 spontaneous effect Effects 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
230000002159 abnormal effect Effects 0.000 description 9
208000026935 allergic disease Diseases 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000009610 hypersensitivity Effects 0.000 description 9
208000015004 muscle tenderness Diseases 0.000 description 9
238000010984 neurological examination Methods 0.000 description 9
238000003825 pressing Methods 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000035807 sensation Effects 0.000 description 9
239000003826 tablet Substances 0.000 description 9
210000000836 trigeminal nuclei Anatomy 0.000 description 9
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 8
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 8
230000002411 adverse Effects 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
238000005259 measurement Methods 0.000 description 8
125000000896 monocarboxylic acid group Chemical group 0.000 description 8
230000008533 pain sensitivity Effects 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
230000035945 sensitivity Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
208000027109 Headache disease Diseases 0.000 description 7
238000010171 animal model Methods 0.000 description 7
230000009850 completed effect Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000003834 intracellular effect Effects 0.000 description 7
210000004914 menses Anatomy 0.000 description 7
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 7
238000012545 processing Methods 0.000 description 7
208000020016 psychiatric disease Diseases 0.000 description 7
230000000284 resting effect Effects 0.000 description 7
210000002435 tendon Anatomy 0.000 description 7
230000000007 visual effect Effects 0.000 description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
239000011575 calcium Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
238000003745 diagnosis Methods 0.000 description 6
230000007717 exclusion Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
210000003715 limbic system Anatomy 0.000 description 6
230000035479 physiological effects, processes and functions Effects 0.000 description 6
239000003380 propellant Substances 0.000 description 6
238000011160 research Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
206010028813 Nausea Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000004075 alteration Effects 0.000 description 5
229940024606 amino acid Drugs 0.000 description 5
210000000133 brain stem Anatomy 0.000 description 5
230000001055 chewing effect Effects 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
230000007515 enzymatic degradation Effects 0.000 description 5
230000000494 facilitatory effect Effects 0.000 description 5
210000003128 head Anatomy 0.000 description 5
238000001802 infusion Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
230000008693 nausea Effects 0.000 description 5
239000002858 neurotransmitter agent Substances 0.000 description 5
230000000392 somatic effect Effects 0.000 description 5
230000035882 stress Effects 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
210000000225 synapse Anatomy 0.000 description 5
210000003901 trigeminal nerve Anatomy 0.000 description 5
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
208000006561 Cluster Headache Diseases 0.000 description 4
206010016059 Facial pain Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
206010043269 Tension headache Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000006399 behavior Effects 0.000 description 4
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
230000009956 central mechanism Effects 0.000 description 4
208000018912 cluster headache syndrome Diseases 0.000 description 4
208000012790 cranial neuralgia Diseases 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000005284 excitation Effects 0.000 description 4
239000007789 gas Substances 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000013101 initial test Methods 0.000 description 4
208000014674 injury Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000002483 medication Methods 0.000 description 4
210000000337 motor cortex Anatomy 0.000 description 4
208000004296 neuralgia Diseases 0.000 description 4
208000021722 neuropathic pain Diseases 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
230000008052 pain pathway Effects 0.000 description 4
230000008058 pain sensation Effects 0.000 description 4
230000007310 pathophysiology Effects 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
230000037081 physical activity Effects 0.000 description 4
230000001376 precipitating effect Effects 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
238000012552 review Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
210000002027 skeletal muscle Anatomy 0.000 description 4
210000002460 smooth muscle Anatomy 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000000946 synaptic effect Effects 0.000 description 4
210000001103 thalamus Anatomy 0.000 description 4
230000001755 vocal effect Effects 0.000 description 4
IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 3
102000003922 Calcium Channels Human genes 0.000 description 3
108090000312 Calcium Channels Proteins 0.000 description 3
206010013654 Drug abuse Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
206010049816 Muscle tightness Diseases 0.000 description 3
229940099433 NMDA receptor antagonist Drugs 0.000 description 3
206010054956 Phonophobia Diseases 0.000 description 3
206010034960 Photophobia Diseases 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000000763 evoking effect Effects 0.000 description 3
230000037406 food intake Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000002045 lasting effect Effects 0.000 description 3
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
230000001991 pathophysiological effect Effects 0.000 description 3
230000009955 peripheral mechanism Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000011514 reflex Effects 0.000 description 3
230000008521 reorganization Effects 0.000 description 3
230000003252 repetitive effect Effects 0.000 description 3
229940127558 rescue medication Drugs 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
210000001044 sensory neuron Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
208000011117 substance-related disease Diseases 0.000 description 3
HJJOBGICUREWHC-UHFFFAOYSA-N synthalin Chemical compound Cl.Cl.NC(N)=NCCCCCCCCCCN=C(N)N HJJOBGICUREWHC-UHFFFAOYSA-N 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000008536 thermal pain sensitivity Effects 0.000 description 3
206010044652 trigeminal neuralgia Diseases 0.000 description 3
230000009278 visceral effect Effects 0.000 description 3
102000009346 Adenosine receptors Human genes 0.000 description 2
108050000203 Adenosine receptors Proteins 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
102000010183 Bradykinin receptor Human genes 0.000 description 2
108050001736 Bradykinin receptor Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010052805 Drug tolerance decreased Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
102000004300 GABA-A Receptors Human genes 0.000 description 2
108090000839 GABA-A Receptors Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108700002232 Immediate-Early Genes Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000000079 Kainic Acid Receptors Human genes 0.000 description 2
108010069902 Kainic Acid Receptors Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
201000002481 Myositis Diseases 0.000 description 2
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
229940127307 Noncompetitive NMDA Receptor Antagonists Drugs 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002390 adhesive tape Substances 0.000 description 2
210000003766 afferent neuron Anatomy 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229960002504 capsaicin Drugs 0.000 description 2
235000017663 capsaicin Nutrition 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
150000001924 cycloalkanes Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
MKXZASYAUGDDCJ-NJAFHUGGSA-N dextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-NJAFHUGGSA-N 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
229960004943 ergotamine Drugs 0.000 description 2
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
230000002461 excitatory amino acid Effects 0.000 description 2
239000003257 excitatory amino acid Substances 0.000 description 2
230000009540 excitatory neurotransmission Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000010304 firing Methods 0.000 description 2
210000001222 gaba-ergic neuron Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000000575 glycinergic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002085 irritant Substances 0.000 description 2
231100000021 irritant Toxicity 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
206010052787 migraine without aura Diseases 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
230000008345 muscle blood flow Effects 0.000 description 2
239000003158 myorelaxant agent Substances 0.000 description 2
210000004237 neck muscle Anatomy 0.000 description 2
230000007230 neural mechanism Effects 0.000 description 2
230000008587 neuronal excitability Effects 0.000 description 2
239000000236 nitric oxide synthase inhibitor Substances 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000002474 noradrenergic effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000003950 pathogenic mechanism Effects 0.000 description 2
230000008289 pathophysiological mechanism Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000008288 physiological mechanism Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920006254 polymer film Polymers 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
125000003259 prostaglandin group Chemical group 0.000 description 2
210000001609 raphe nuclei Anatomy 0.000 description 2
230000026416 response to pain Effects 0.000 description 2
230000036280 sedation Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000003238 somatosensory effect Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
229960003708 sumatriptan Drugs 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
230000003867 tiredness Effects 0.000 description 2
208000016255 tiredness Diseases 0.000 description 2
230000006411 tonic activation Effects 0.000 description 2
230000018405 transmission of nerve impulse Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
102000003678 AMPA Receptors Human genes 0.000 description 1
108090000078 AMPA Receptors Proteins 0.000 description 1
229940124049 Adenosine A2 receptor antagonist Drugs 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
208000001387 Causalgia Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010064888 Cervicogenic headache Diseases 0.000 description 1
102000034573 Channels Human genes 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
102000011045 Chloride Channels Human genes 0.000 description 1
108010062745 Chloride Channels Proteins 0.000 description 1
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 description 1
229940127486 Competitive NMDA Receptor Antagonists Drugs 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
229940121869 GABA A receptor agonist Drugs 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
102400001370 Galanin Human genes 0.000 description 1
101800002068 Galanin Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
229940123572 Kainate receptor antagonist Drugs 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
241001490312 Lithops pseudotruncatella Species 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
102100037611 Lysophospholipase Human genes 0.000 description 1
101710151321 Melanostatin Proteins 0.000 description 1
206010049565 Muscle fatigue Diseases 0.000 description 1
HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
108050006653 Neurokinin NK3 receptors Proteins 0.000 description 1
102100029409 Neuromedin-K receptor Human genes 0.000 description 1
102400000064 Neuropeptide Y Human genes 0.000 description 1
102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
229940123921 Nitric oxide synthase inhibitor Drugs 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
206010033433 Pain in jaw Diseases 0.000 description 1
206010033474 Pain of skin Diseases 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 1
108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
206010036313 Post-traumatic headache Diseases 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043268 Tension Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000826860 Trapezium Species 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
230000000307 algesic effect Effects 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
210000002226 anterior horn cell Anatomy 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229960003589 arginine hydrochloride Drugs 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
231100000749 chronicity Toxicity 0.000 description 1
238000005352 clarification Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
108091008710 cutaneous receptors Proteins 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000008451 emotion Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108091008708 free nerve endings Proteins 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000000917 hyperalgesic effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000009539 inhibitory neurotransmission Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000030214 innervation Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
230000008316 intracellular mechanism Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012886 linear function Methods 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
210000001352 masseter muscle Anatomy 0.000 description 1
210000003784 masticatory muscle Anatomy 0.000 description 1
210000001595 mastoid Anatomy 0.000 description 1
230000008534 mechanical pain sensitivity Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000000412 mechanoreceptor Anatomy 0.000 description 1
108091008704 mechanoreceptors Proteins 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
102000006239 metabotropic receptors Human genes 0.000 description 1
108020004083 metabotropic receptors Proteins 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000000966 norepinephrine reuptake Effects 0.000 description 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000008756 pathogenetic mechanism Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000002856 peripheral neuron Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003009 phosphonic acids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000005215 presynaptic neuron Anatomy 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000013849 propane Nutrition 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000003304 psychophysiological effect Effects 0.000 description 1
239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
230000031893 sensory processing Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000001629 sign test Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
210000002538 spinal trigeminal nucleus Anatomy 0.000 description 1
230000008925 spontaneous activity Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000001548 stomatognathic system Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000008293 synaptic mechanism Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000003363 transsynaptic effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002593733A 1996-11-05 1997-11-04 Procede de traitement de cephalees du type par tension nerveuse Abandoned CA2593733A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKDK1243/96		1996-11-05
DK124396		1996-11-05
CA2270531A CA2270531C (fr)	1996-11-05	1997-11-04	Procede de traitement de cephalees du type par tension nerveuse

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2270531A Division CA2270531C (fr)	1996-11-05	1997-11-04	Procede de traitement de cephalees du type par tension nerveuse

Publications (1)

Publication Number	Publication Date
CA2593733A1 true CA2593733A1 (fr)	1998-05-14

Family

ID=38445952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002593733A Abandoned CA2593733A1 (fr)	1996-11-05	1997-11-04	Procede de traitement de cephalees du type par tension nerveuse

Country Status (1)

Country	Link
CA (1)	CA2593733A1 (fr)

1997
- 1997-11-04 CA CA002593733A patent/CA2593733A1/fr not_active Abandoned

Publication	Publication Date	Title
US6284794B1 (en)	2001-09-04	Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
AU734490B2 (en)	2001-06-14	A method for treating tension-type headache
EP1463528B1 (fr)	2012-04-11	Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur
US6602911B2 (en)	2003-08-05	Methods of treating fibromyalgia
Kosharskyy et al.	2013	Intravenous infusions in chronic pain management
JPH06501454A (ja)	1994-02-17	グリシン／ｎｍｄａ受容体複合体の機能性拮抗剤による情緒障害の治療
US10265304B2 (en)	2019-04-23	Nootropic compositions for improving memory performance
CZ2004362A3 (cs)	2005-01-12	Použití derivátů amidů kyseliny valproové a amidů kyseliny 2-valproenové pro léčbu nebo prevenci bolesti a/nebo bolesti hlavy
US20040087558A1 (en)	2004-05-06	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU771266B2 (en)	2004-03-18	A method for treating tension-type headache
CA2593733A1 (fr)	1998-05-14	Procede de traitement de cephalees du type par tension nerveuse
HK1113080A (en)	2008-09-26	A method for treating tension-type headache
Attal et al.	2006	Treatment of neuropathic pain
Kudoh et al.	2000	Current perception thresholds of epileptic patients treated with valproate
MX2008004197A (en)	2008-09-02	Milnacipran for the long-term treatment of fibromyalgia syndrome

Legal Events

Date	Code	Title	Description
2007-07-20	EEER	Examination request
2011-10-31	FZDE	Dead